Posted by Michael Wonder on 21 Feb 2018
Mylan receives tentative approval for combination HIV treatment DTG/FTC/TAF under FDA's PEPFAR program
20 February 2018 - Mylan's DTG/FTC/TAF will be the first TAF-based fixed-dose combination to be offered to patients in developing countries being treated for HIV.
Global pharmaceutical company Mylan today announced receipt of tentative approval from the U.S. FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its new drug application for dolutegravir, emtricitabine, and tenofovir alafenamide tablets, 50 mg/200 mg/25 mg.
The anti-retroviral will be immediately available in developing countries as a first-line regimen for people being treated for HIV/AIDS.
